New Antiretroviral Therapies and Classes. Douglas G. Fish, MD Albany Medical College Albany, NY Cali,, Colombia March 29, 2007
|
|
- Jerome Freeman
- 5 years ago
- Views:
Transcription
1 New Antiretroviral Therapies and Classes Douglas G. Fish, MD Albany Medical College Albany, NY Cali,, Colombia March 29, 27
2 Overview New therapies existing classes Investigational antiretrovirals Monoclonal antibody Maturation inhibitor Integrase inhibitors CCR5 inhibitors CXCR4 inhibition HBV: Entecavir HIV activity?
3 Credit Clinical Care Options, LLC and Medical Education Collaborative Website:
4 The 14th Conference on Retroviruses and Opportunistic Infections Los Angeles, California February 25-28, 27 Slides with this color scheme were downloaded from: 4
5 Targets of HIV Therapy Entry Inhibitors: Fusion Inhibition Nucleus Integrase Inhibitors Entry Inhibitors: CCR5 & CXCR4 blockers HIV RNA Reverse transcriptase DNA Protease CD4+ T-Cell Reverse transcriptase inhibitors: NRTIs (nucleosides, nucleotides) NNRTIs Protease inhibitors
6 RESIST 1 and 2: Week 96 Data From Phase III Studies of TPV/RTV Patients failing PI-containing HAART; VL > 1; any CD4+ Baseline genotypic resistance testing* Best PI choice HIV resistance expert panel Preselection of regimen by investigator: CPI + OBR (± ENF) Computerized randomization to OBR plus TPV/RTV arm CPI arm LPV/RTV, IDV/RTV, SQV/RTV, APV/RTV Failures in CPI arm after Week 8 eligible for TPV/RTV in rollover study *Entry criteria: 3-class experienced; 1 primary PI mutation: 3N, 46I/L, 48V, 5V, 82A/F/L/T, 84V, or 9M; 2 mutations: 33, 82, 84, or 9. Gazzard B, et al. Glasgow 26. Abstract P23. Hicks CB, et al. Lancet. 26;368:
7 CD4 Cell Responses at Week 48 (LOCF) p<.1 13 th CROI, Denver, CO 26 Hicks CB et al. Lancet 26;368:
8 Intracranial Hemorrhage (ICH) Incidence in tipranavir trials.26/1 person-years of exposure (95% CI.9,.82) Review of U.S. Veterans Healthcare System & Medi-Cal between October 1997 and December 23 VA:.7 Med-Cal.23.7 (.5,.1).23 (.2,.25) Similar rates to TPV pre-approval trials More common in age > 4 and persons with AIDS Fultz S et al. 14 th CROI, Los Angeles, 27; Abstract 819.
9 POWER 1 and 2: Study Design PI-, NRTI- and NNRTIexperienced 1 PI mutation (IAS-USA) PI-based regimen VL > 1 copies/ml Investigatorselected CPI(s) + OBR (without NNRTIs) Investigator-selected CPI(s) + OBR DRV/RTV 4/1 mg QD + OBR DRV/RTV 8/1 mg QD + OBR DRV/RTV 4/1 mg BID + OBR DRV/RTV 6/1 mg BID + OBR DRV/RTV 6/1 mg BID provided greatest virologic response in Wk 24 analysis; FDA-approved dose for treatment-experienced experienced pts VL, viral load; OBR, optimized background regimen (NRTIs ± enfuvirtide) Lazzarin A, et al. IAC 26. Abstract TUAB14.
10 Patients with VL <5 Copies/mL Over Time to Week 48 (ITT-TLOVR) Lazzarin A, et al. XVI IAC Toronto, Canada, Aug , 26; Abst. TUAB14.
11 POWER 1 and 2: % of Pts Achieving VL < 5 at Wk 24 on DRV/RTV* vs CPIs* Patients With VL < 5 copies/ml at Week 24 (%) % DRV/RTV 16% 12% FPV/RTV LPV/RTV 7% ATV/RTV 4% SQV/RTV n = * + Optimized background regimen = 2 NRTIs ± ENF Lefebvre E, et al. Glasgow 26. Poster P29.
12 POWER: Subgroup Analyses of Response to Darunavir/r 6/1 BID Overall ENF Used (Naive) ENF Not Used 3 Primary PI Mut No Sensitive ARVs in OBR POWER-1 Cohort [1] 22% (n = 18) 19% (n = 36) 9% (n = 35) % (n = 9) 17% (n = 12) Darunavir/r 6/1 BID 53% (n = 6) 18% (n = 6) 63% (n = 19) 56% (n = 34) 59% (n = 29) Control POWER-2 Cohort [2] 39% (n = 57) 7% (n = 53) 7% (n = 14) 3% (n = 2) 4% (n = 24) 35% (n = 23) 7% (n = 28) % (n = 7) 18% (n = 11) 64% (n = 14) Patients With HIV-1 RNA < 5 copies/ml at Wk 24 (%) (ITT NC=F) 1. Katlama C, et al. IAS 25. Abstract WeOaLB Wilkin T, et al. ICAAC 25. Abstract H Patients With HIV-1 RNA < 5 copies/ml at Week 24 (%) 1
13 Brecanavir (BCV, GW64385): Open-label, Phase II Study Investigational PI with activity in vitro vs. many PI- resistant viruses Open-label, single-arm study; n=31 BCV/RTV 3/1 mg BID for 48 weeks plus 2 NRTIs; 8- and 24-week interim analysis Entry criteria: ART-na naïve or - experienced HIV RNA >1 c/ml CD4+ >2 cells/mm 3 Virologic response ITT (MD=F) x <4 c/ml <5 c/ml Ward D, et al. 45 th ICAAC, Washington DC 25, #H-412
14 Brecanavir (BCV, GW64385): Open-label, Phase II Study At baseline: Median (IQR) HIV RNA: 4.71 ( ) log 1 c/ml; PI resistant group with HIV RNA 3.98 log Median (IQR) CD4+: 311 (26 46) cells/mm 3 6/31 patients PI resistant: median primary PI mutations 2, LPV fold-change of 8.31 Results ITT (MD-F) <4 and <5 c/ml: : 81% and 77%, respectively Larger phase II/III study in patients with higher-level PI resistance is ongoing Ward D, et al. 45 th ICAAC, Washington DC 25, #H-412
15 Brecanavir Resistance Brecanavir is chemically related to amprenavir and darunavir Similar resistance profiles to amprenavir and darunavir Tipranavir mutation V82L/T had limited effect on susceptibility to darunavir and brecanavir Elston R et al. 14 th CROI Los Angeles, 27; Abstract 62.
16 TMC125 - Etravirine Diaryl pyrimidine derivative an NNRTI In vitro characteristics Potent activity against HIV EC 5 WT HIV-1: 1.4 nmol/l < 5-fold 5 reduction in susceptibility against K13N, Y181C, Y188L, and L1I Phase 1 pharmacokinetics Elimination half-life: life: 3-4 hours Steady state attained within 5 days Metabolized by cytochrome P45 CYP3A Protein binding de Bethune MP, et al. ICAAC 2. Abstract Piscitelli S, et al. IWCPHIVT 22. Abstract 5.3.
17 Response to Etravirine in Patients With NNRTI and PI Resistance (ITT:NC=F) N = 199 HIV-infected patients with NNRTI resistance and 3 primary PI mutations Median fold NNRTI-R Nevirapine: 61 Efavirenz: 41 Etravirine: 1.7 Mean (± SE) Change in VL (log 1 c/ml) Weeks *P =.18 P = * -1.1 OBR alone (n = 4) Etravirine 4 mg BID (n = 8) Etravirine 8 mg BID (n = 79) Cohen C. British HIV Association, 26. Abstract 2.
18 Effect of Baseline Resistance on Response to Etravirine Number of Baseline NNRTI Mutations (Number of Patients) (n = 15) 1 (n = 18) 2 (n = 17) 3 (n = 29) Viral Load Reduction at Week 24 (log 1 copies/ml) Each of the following mutations, always in combination with up to 4 other mutations, was associated with a mean FC > 1 K11P, V179E, V179F, Y181I, Y181V, G19S, M23L For V179E, V179F, G19S, or M23L, the additional mutations always included Y181C when the FC > 1 No single NNRTI drug resistance mutation was associated with FC > 1 Required multiple mutations ( ( 4) Vingerhoets J, et al. Resistance Workshop, 26. Abstract 52.
19 PA-457: Investigational Maturation Inhibitor Disrupts a late step in gag processing involving conversion of the capsid precursor (p25) to a mature capsid protein (p24) Orally-bioavailable bioavailable, T ½ = 6 h 1-day dose-ranging study 25, 5, 1, 2 mg QD (n=6/arm)( vs placebo (n=8)( Entry criteria: CD4+ >2 cells/mm 3, HIV RNA 5 25, c/ml,, ART-na naïve or off >12 wks Beatty G, et al. 45 th ICAAC, Washington DC 25, #H-416d
20 PA-457: Investigational Maturation Inhibitor Results At BL: Median CD cells/mm 3 ; HIV RNA 4.73 log 1 c/ml VL with 2-day 2 delay after first dose, with peak VL 2 3 days after last dose Plasma concentration best predictor of response One outlier at 2 mg dose with good levels and no response No new resistance mutations or drug-specific AEs Phase II/III study to start in 26 Change from BL (log 1 ) DOSE (mg) PBO * Median Mean p=.2 p=.4 Beatty G, et al. 45 th ICAAC, Washington DC 25, #H-416d p<.1
21 TNX-355 Humanized murine mab 5A8 IgG subtype 4 Recognizes unique epitope in domain 2 of CD4 Inhibits post-binding entry of HIV-1
22 TNX-355.1: Virologic and Immunologic Effects of TNX mg/kg 25. mg/kg Mean Change in HIV-1 RNA (log 1 copies/ml) Mean Change in CD4+ Cell Count (cells/mm 3 ) Days Days Kuritzkes D, et al. J Infect Dis. 24;189(2):
23 Absorption, Metabolism and Excretion of MK Raltegravir MK-518: HIV-1 1 integrase strand transferase inhibitor 8 HIV males: Oral dose of 2 mg [14C]MK-518, in vitro studies used microsomes Results: Excreted in both urine (32%) and feces (51%) Eliminated principally via glucuronidation Main mechanism of clearance: UDP-UGT1A1 UGT1A1- mediated glucuronidation MK-518 is not expected to exhibit drug interactions with P45 enzymes Kassahun K, et al. 46th ICAAC, San Francisco, CA, Sept. 27-3, 26; Abst. A-372.
24 BENCHMRK 1 and 2: Trial Design 2 identical ongoing Phase III studies (in different countries) Randomized (2:1), double-blind, placebo controlled ART-Experienced adult patients Documented genotypic/phenotypic resistance to 1 drug in each of 3 classes (NNRTI + NRTI + PI) HIV RNA > 1 copies/ml Raltegravir (4 mg BID) + OBT (n=462) Placebo + OBT (n=237) Primary Endpoints (Week 16): HIV RNA and CD4 counts Adverse experiences Patients virologically failing after 16 weeks could enter open-label RAL arm Cooper D and Steigbigel R, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 15aLB and 15bLB. 24
25 Baseline Patient Characteristics BENCHMRK 1 & 2 BENCHMRK-1 BENCHMRK-2 RAL (n = 232) Placebo (n = 118) RAL (n = 23) Placebo (n = 119) Mean Age, yrs (SD) % Male % Caucasian 46 (9) (8) (9) (8) 9 65 Mean CD4 Count, cells/mm 3 GM Viral Load, copies/ml (log 1 HIV RNA) % AIDS Median Yrs of Prior ARTs (median # ART) % Hep B+/% Hep C (4.6) (12) 8/ (4.5) 9 1 (12) 4/ (4.7) 91 1 (12) 1/ (4.7) 92 1 (12) 3/4 % GSS /1 % PSS /1 % new enfuvirtide in OBT % new darunavir in OBT 3/33 19/ /41 18/ /44 1/ /4 19/ GSS/PSS = total ART in OBT to which pt s virus showed geno/phenotypic sensitivity by Phenosense GT assay. Enfuvirtide and darunavir use in naïve patients were each counted as + 1 active agent and added to GSS/PSS Cooper D and Steigbigel R, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 15aLB and 15bLB. 25
26 Percent <4 and <5 Copies/mL (ITT, NC=F) BENCHMRK 1 & 2 1 RAL <4 RAL <5 BENCHMRK 1 Placebo <4 Placebo <5 1 BENCHMRK 2 % of Patients <4 Copies/mL Weeks (P<.1 at Week 16 for all parameters) Weeks Cooper D and Steigbigel R, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 15aLB and 15bLB. 26
27 BENCHMRK 1 & 2 Combined Efficacy (1) % Patients with HIV RNA <4 copies/ml at Week 16 by Selected ARTs in OBT* Subgroup n % of Patients Overall Efficacy Data Efficacy by ARTs in OBT Enfuvirtide Darunavir : First Use in OBT - : No Use in OBT * BENCHMRK 1 & 2 with virologic failures carried forward RAL Placebo Cooper D and Steigbigel R, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 15aLB and 15bLB. 27
28 BENCHMRK 1 & 2 Combined Efficacy (2) % Patients with HIV RNA <4 copies/ml at Week 16 by PSS/GSS of OBT* Subgroup n % of Patients Overall Efficacy Data (PSS) 1 2 or more (GSS) 1 2 or more : First Use in OBT - : No Use in OBT * BENCHMRK 1 & 2 with virologic failures carried forward RAL Placebo Cooper D and Steigbigel R, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 15aLB and 15bLB. 28
29 BENCHMRK 1 & 2 Combined Efficacy (3) % Patients with HIV RNA <4 copies/ml at Week 16 by Baseline HIV RNA and CD4 Cell Count* Subgroup n % of Patients Overall Efficacy Data Baseline Plasma HIV RNA (copies/ml) < 1, > 1, Baseline CD4 Cell Counts (cells/mm3) 5 > 5 and 2 > * BENCHMRK 1 & 2 with virologic failures carried forward RAL Placebo Cooper D and Steigbigel R, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 15aLB and 15bLB. 29
30 Clinical Adverse Events (%) BENCHMRK 1 & 2 BENCHMRK-1 BENCHMRK-2 Adverse Experiences RAL (n = 232) Placebo (n = 118) RAL (n = 23) Placebo (n = 119) Mean Exposure (weeks) Any AE Drug-related* AE Serious AE Serious drug-related* AE Death AE leading to discontinuation *Drug-related = any grade; relationship to drug by investigator to RAL/placebo ± OBT or to OBT alone; No significant differences between arms for any AE Cooper D and Steigbigel R, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 15aLB and 15bLB. 3
31 Drug Related Clinical Adverse Events (%) (3% - mild, moderate and severe) BENCHMRK 1 & 2 BENCHMRK-1 BENCHMRK-2 RAL (n = 232) Placebo (n = 118) RAL (n = 23) Placebo (n = 119) Mean Exposure (Wks) Abdominal Distension Abdominal Pain Diarrhea Nausea Headache Fatigue Cooper D and Steigbigel R, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 15aLB and 15bLB. 31
32 Laboratory Abnormalities (%) ( 1 % in at least one treatment group) BENCHMRK 1 & 2 BENCHMRK-1 BENCHMRK-2 Test Toxicity Criteria* RAL (n = 232) Placebo (n = 118) RAL (n = 23) Placebo (n = 119) ANC Hgb <75 c/ul <7.5 gm/dl LDL-C** Chol** TG** 19 mg/dl >3 mg/dl >75 mg/dl Creatinine Panc. Amylase 1.9 x ULN 2.1 x ULN AST x ULN (Gr 2) 5.1 x ULN ALT x ULN (Gr 2) 5.1 x ULN *Grade 3 or 4 per DAIDS toxicity criteria for all tests except grade 2-4 for AST and ALT **Fasting Cooper D and Steigbigel R, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 15aLB and 15bLB. 32
33 Elvitegravir (GS 9137) Study Design Phase II study Randomized, partially-blinded (EVG dose) 278 ARV-experienced patients HIV RNA 1 copies/ml; Any CD4 cell count; 1 protease resistance mutation All patients received OBT* Stratified by T-2 use in OBT CPI** (n=63) EVG (2mg) (n=71) EVG (5mg) (n=71) EVG (125mg) (n=73) Primary endpoint: time-weighted average change from baseline in HIV RNA through 24 weeks (DAVG 24 ) *OBT = NRTIs +/- T-2; NNRTIs not allowed in OBT; PIs initially barred in EVG arms **CPI included 49% darunavir, 27% tipranavir Zolopa A, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Abst. 143LB. 33
34 EVG: Phase II Study Outcomes EVG (2 mg) stopped due to inferior outcomes EVG (5 and 125mg) superior to a boosted PI at week 16 ITT CPI/r 5 mg 125 mg DAVG 16 mean log drop (P=.9) (P=.1) All patients allowed to add a boosted PI as drug-drug interaction data available DAVG: Time-weighted average change from baseline in HIV RNA Zolopa A, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Abst. 143LB. 34
35 Adverse Events and Laboratory Abnormalities EVG: Phase II Week 24 CPI (n = 63) EVG 2 mg (n = 71) EVG 5 mg (n = 71) EVG 125 mg (n = 73) AEs leading to Drug D/C 2 (3%) 1 (1%) 2 (3%) 1 (1%) Grade 3/4 AEs 9 (14%) 13 (18%) 9 (13%) 1 (14%) Grade 3/4 lab abnormalities 2 (32%) 21 (3%) 15 (21%) 15 (21%) Zolopa A, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Abst. 143LB. 35
36 Integrase Resistance Mutations Data from Merck Phase III studies 1 : Virologic rebound in 16% RAL versus 51% on control arm Two pathways to resistance: Primary N155H Q148K/R/H Secondary E92Q, V151I, T97A, G163K, L74M G14S/A, E138K Elvitegravir resistance mutations in vitro 2 Two pathways to resistance: Primary T66I E92Q Secondary F121Y, S153Y, R263K S147G, H51Y, E157Q Concern for cross resistance between these by in vitro fold change 1. Cooper D and Steigbigel R, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 15aLB and 15bLB. 2. Jones G, et al. Ibid. Abst
37 MOTIVATE 1 & 2: Trial Design MOTIVATE 1& 2 2 identical ongoing Phase IIb/III studies Randomized (1:2:2), double-blind, placebo controlled 176 ARV-experienced patients R5 HIV-1 infection (44% screen failures) HIV-1-RNA 5, copies/ml Stable pre-study ARV regimen, or no ARVs for 4 weeks Resistance to and/or 6 months experience with 1 ARV from 3 classes ( 2 for PIs) All received OBT* Stratified by ENF use and HIV-1 RNA < and 1, copies/ml Placebo (n=29) MVC 15mg QD (n=414) MVC 15mg BID (n=426) Primary endpoint at 24 weeks: Mean change from baseline in HIV-1 RNA *OBT = optimized background therapy of 3 6 ARVs (PK boosting doses of RTV not counted as an ARV) Pts receiving a PI (except TPV) and/or delavirdine in their OBT received 15 mg of MVC, all others received 3 mg of MVC Nelson M and Lalezari J, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 14aLB and 14bLB. 37
38 Demographics and Baseline Characteristics MOTIVATE 1 Treated N = 585 Placebo (n = 118) MVC QD (n = 232) MVC BID (n = 235) Mean age, yrs (range) 46 (31 71) 46 (19 75) 46 (25 69) Male, n (%) 16 (9) 21 (91) 212 (9) White, n (%) 99 (84) 187 (81) 197 (84) Median CD4 count*, cells/mm 3 (range) Mean HIV-1 RNA*, log 1 copies/ml (range) 163 (1 675) 4.84 ( ) 168 (1 812) 4.85 ( ) 15 (2 678) 4.86 ( ) Enfuvirtide in OBT, % active drugs in OBT, % Two patients (1 MVC QD, 1 placebo) were assigned to the wrong treatment group due to a transcription error * Calculated for each patient as the mean of up to three pre-dose assessments (screening, randomization, and baseline) According to overall susceptibility score Nelson M, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Abst. 14aLB. 38
39 39
40 MOTIVATE 1& 2 Percentage of Patients with HIV-1 RNA < 5 copies/ml by Number of Active Drugs in OBT* Patients (%) N= Placebo + OBT MVC QD + OBT MVC BID + OBT Number of active drugs in OBT* * Based on overall susceptibility score (LOCF) Nelson M and Lalezari J, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 14aLB and 14bLB. 4
41 Safety Analyses Unadjusted for Duration of Exposure MOTIVATE 1 All causalities and severities Placebo + OBT N = 118 MVC QD + OBT N = 232 MVC BID + OBT N = 235 Total exposure, patient-years Patients with AEs 84% 88% 91% Patients discontinuing due to AEs 5% 5% 4% Patients with grade 3 AEs 24% 16% 21% Patients with grade 4 AEs 7% 8% 9% Patients with SAEs 17% 13% 16% Patients with Category C events 4% 4% 3% Deaths*.9%.9%.4% Nelson M, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Abst. 14aLB. 41
42 Number of Category C Events MOTIVATE 2 Event, n Placebo (n = 91) MVC QD (n = 182) MVC BID (n =+ OBT N = 191 Total exposure, patient-years Herpes virus infection Esophageal candidiasis Cytomegalovirus (CMV) infection* 1 Mycobacterium avium 2 1 Recurrent bacterial pneumonia 3 Pneumocystis jiroveci pneumonia 1 Mycobacterial infection 1 Cryptosporidium enteritis 1 Kaposi s sarcoma Lymphoma 1 1 Total number of events Patients (% of patients) 9 patients (9.9%) 16 patients(8.8%) 11 patients(5.8%) * Includes CMV infection, CMV gastrointestinal infection, and CMV retinitis Lalezari J, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Abst. 14bLB. 42
43 MOTIVATE 1& 2 Change in CD4 Cell Count from Baseline to Time of Treatment Failure Tropism result, Baseline Treatment Failure All treatment failures R5 R5 R5 D/M or X4 Mean change in CD4 count from baseline, cells/mm 3 in patients with treatment failure Placebo (n = 29) +14 (n = 97) +15 (n = 8) +67 (n = 4) MVC QD (n = 414) +49 (n = 68) +61 (n = 18) +37 (n = 31) MVC BID (n = 426) +71 (n = 77) +138 (n = 17) +56 (n = 32) Approximately 8% of patients had a change in tropism result between screening and baseline, demonstrating the change in background tropism over a 4 6 week period in this population Response to maraviroc treatment in these patients was consistent with the results of study A4129 in patients with D/M-tropic virus 2 Data excludes patients who had no tropism result at time of failure and patients with non-r5 virus at baseline 1. Nelson M and Lalezari J, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Absts. 14aLB and 14bLB. 2. Mayer H, et al. XVI IAC, Toronto, Canada, Aug , 26, Abst. THLB
44 XACT Study CXCR4 inhibitor AMD117 Design: AMD117 dose finding study Results: AMD117 monotherapy x 1 days in 1 pts with CXCR4 (X4) virus AMD117 dose: 2mg BID (n=8) or 1mg BID (n=2) 4 of 9 pts achieved 1 log 1 c/ml reduction in X4 rlu* after 1 days of Tx Responders achieved a median 1.5 log 1 c/ml reduction in X4 rlu (Range: -.72 to -1.9) No significant changes in CD4, CD34, HIV viral load, WBC and R5 rlu* were observed Well tolerated with no drug-related serious adverse events (AEs) or > grade 2 drugrelated AEs observed AMD117 was recently placed on clinical hold by the FDA: liver histology changes observed in animal toxicology *relative luminescence units Moyle G, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Abst
45 Entecavir: HIV Activity? Entecavir (ETV) previously thought to have no HIV activity Study evaluating ETV in HIV ETV potently inhibits HIV in vitro at an IC5 between.1 and 1 nm 3 HIV/HBV pts Tx d with ETV had significant decline in HIV RNA of ~1-3 log 1 copies/ml 1 pt had emergence of M184V mutation while samples for other 2 pts not available At start of ETV, and at 4 and 6 months following start, %, 61% and 1% of HIV clones harbored M184V ETV may have some anti-hiv activity and use of it in HIV/HBV coinfected patients not on HAART may lead to HIV resistance ETV package insert has been modified to reflect this concern McMahon M, et al. 14th CROI, Los Angeles, CA, February 25-28, 27. Abst. 136LB. 45
46 Conclusions New protease inhibitors potent and durable New NNRTI potent if < 3 NNRTI mutations New classes of integrase inhibitors and CCR5 antagonists will likely change treatment paradigms over the next 5 years.
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationHIV Integrase Inhibitors: Current and Future Use. Douglas G. Fish, MD Albany Medical College Cali, Colombia March 13, 2008
HIV Integrase Inhibitors: Current and Future Use Douglas G. Fish, MD Albany Medical College Cali, Colombia March 13, 2008 Which of the following statements about raltegravir is false? a) Raltegravir is
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationHIV Drug Resistance Update 2007
HIV Drug Resistance Update 27 Harry Lampiris, MD Associate Professor of Clinical Medicine, UCSF Infectious Disease Section Department of Medicine San Francisco VA Medical Center Outline Indications for
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationUpdate on HIV-1 Drug Resistance and Tropism Testing
Update on HIV-1 Drug Resistance and Tropism Testing Daniel R. Kuritzkes, MD Section of Retroviral Therapeutics Brigham and Women s Hospital Harvard Medical School ACTHIV 2011: A State-of-the-Science Conference
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationRALTEGRAVIR. October Produced by the London New Drugs Group on behalf of the HIV Drugs and Treatment sub-group of the London HIV Consortium
Page 1 Produced by the London New Drugs Group on behalf of the HIV Drugs and Treatment sub-group of the London HIV Consortium RALTEGRAVIR Contents Summary 1 Background 3 Interactions 3 Clinical efficacy
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationPerspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI)
Perspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI) Gianni Di Perri Dept. de Maladies Infectieuses Universitè de Turin Ospedale Amedeo di Savoia Fusion inhibitors
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationJosep Mallolas Hospital Clínic Barcelona
Nuevos paradigmas en la infección VIH Josep Mallolas Hospital Clínic Barcelona 1. Do you believe, I have to start ARV therapy? Incidence and Mortality of AIDS in Spain HIV and NON-AIDS complications HIV
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationThe New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
The New Agents: Management of Experienced Patients and Resistance Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine T.D. 45 year old man with HIV infection diagnosed in 2000 On multiple
More informationVIKING STUDIES. Efficacy and safety of dolutegravir. treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir treatment-experienced subjects (DTG) in UK/DLG/0083/14e(2) Date of preparation: February 2017 Prescribing information is available at the end of this
More informationResistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,
More informationThe US Food and Drug Administration has
NEW ANTIRETROVIRAL AGENTS FOR TREATMENT-EXPERIENCED PATIENTS * Roy M. Gulick, MD, MPH ABSTRACT Antiretroviral treatment regimens currently available for the treatment of the human immunodeficiency virus
More informationDolutegravir Attributes
Dolutegravir (; S/GSK1349572) in Combination Therapy Exhibits Rapid and Sustained Antiviral Response in Antiretroviral Naïve Adults: 96 Week Results from SPRING 1 (ING112276) Hans Juergen Stellbrink, 1
More informationNew Hope for Treatment Experienced HIV (+) Patients. Treatment Experienced. Drug Resistance: Estimated Prevalence. Patients in the US- Estimate
New Hope for Treatment Experienced HIV (+) Patients Nelson Vergel www.salvagetherapies.org HIV/AIDS Pandemic 23: Adults and Children Living With HIV/AIDS 47% of Cases are Women 15.6% Eastern Europe Western
More informationPrinciples of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada
Principles of HIV Drug Resistance: Resistance to New Drug Classes Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada Why Is It Important to Understand HIV Drug Resistance? 1. Resistance
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationIAC Analyst Presentation
IAC Analyst Presentation David Redfern Chairman, ViiV Healthcare Chief Strategy Officer, GSK July 27, 2012 1 ViiV Healthcare Dr Dominique Limet CEO, ViiV Healthcare July 27, 2012 2 Equity split of 85%
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationIntegrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University
Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationCL Vavro, 1 J Huang, 2 C Avatapally, 1 S Min, 1 and M Ait-Khaled 3. GlaxoSmithKline: 1 Research Triangle Park,NC, USA; 2 Toronto, ON, Canada; 3
Durable Efficacy and Limited Integrase Resistance Evolution in Subjects Receiving Dolutegravir After Failing Prior Integrase Inhibitor (INI) Regimens: Week 48 Results from VIKING-3 CL Vavro, 1 J Huang,
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationPRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon 1 ASM Microbe 2016
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationResistance Characteristics of Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Madrid, November 2016 Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Disclaimer Presentation includes
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationINTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING
INTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING Dr. Danni Kirwan ID/Microbiology SpR St. George s Hospital, London ARV initiation in treatment-naïve patients BHIVA,
More informationKiat Ruxrungtham. Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre
Kiat Ruxrungtham Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre www.iasusa.org; www.aidsinfo.nih.gov; www.clinicaloptions.com; www.clinicaloptions.com/hiv
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationThe results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain
The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable
More informationInvestigator Initiated Study Program (IISP) Project Manager
Alix de Jacquelot alix2j@hotmail.fr Master EUDIPHARM Intern Merck-Sharp&Dohme Project Manager Medical Affairs 3, Avenue Hoche, PARIS Supervised by : Dr Dominique BLAZY dominique_blazy@merck.com Medical
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationAntiretroviral Therapy: New Drugs, New Formulations, New Ideas, New Strategies
Antiretroviral Therapy: ew Drugs, ew Formulations, ew Ideas, ew Strategies Prof. Ian Sanne Director Clinical HIV Research Unit University of the Witwatersrand and Managing Director Right to Care Why We
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationSources of slides and information. roi/main.html. CME slide kit : Rush University Medical Center
Sources of slides and information www.clinicaloptions.com/hiv com/hiv http://www.hivandhepatitis.com/2010_conference/chivandhepatitis conference/c roi/main.html CME slide kit : Rush University Medical
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationScottish Medicines Consortium
Scottish Medicines Consortium darunavir 300mg tablets (Prezista ) No. (378/07) Tibotec (a division of Janssen-Cilag Ltd) 4 May 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationTransmission of integrase resistance HIV
Transmission of integrase resistance HIV Charles Boucher, MD, PhD Clinical Virology, Dept. Viroscience, Erasmus Medical Center, Erasmus Universiy, The Netherlands Major resistance mutations (Stanford)
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationEfficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results
Efficacy and Safety of Doravirine 1mg QD vs Efavirenz 6mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results Jose M. Gatell, Francois Raffi, Andreas Plettenberg, Don Smith, Joaquin Portilla,
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationInvestigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents
Investigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents Joseph J. Eron MD Professor of Medicine University of North Carolina Chapel Hill, North Carolina Learning Objectives
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More informationCongress report: XV Congreso Panamericano De Infectología the PROGRESS Study
HAART, HIV correlated pathologies and other infections Marco Borderi*, Adriano Lazzarin Congress report: XV Congreso Panamericano De Infectología the PROGRESS Study Infectious Diseases Unit S. Orsola Hospital
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationIntroduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More information